Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

$Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL$

Michael Milone - Immunotherapy of Cancer Using Genetically Enhanced T CellsПодробнее

Michael Milone - Immunotherapy of Cancer Using Genetically Enhanced T Cells

Engineered T Cell with CARs and TCRs for Hematologic MalignancyПодробнее

Engineered T Cell with CARs and TCRs for Hematologic Malignancy

Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALLПодробнее

$Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL$

Long-term outcomes of anti-CD19 CAR-T in R/R CLLПодробнее

Long-term outcomes of anti-CD19 CAR-T in R/R CLL

Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLLПодробнее

$Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL$

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignanciesПодробнее

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

CAR T-Cell Therapy for Relapsed/Refractory CLLПодробнее

$CAR T-Cell Therapy for Relapsed/Refractory CLL$

Findings for CD19-Targeted CAR T Cells in Combination With Ibrutinib in CLLПодробнее

Findings for CD19-Targeted CAR T Cells in Combination With Ibrutinib in CLL

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLLПодробнее

Dr. Wierda on Using CD19-Targeted CAR T Cells in CLL

Current research on CD19 targeted CAR T-cells in relapsed B-cell ALLПодробнее

Current research on CD19 targeted CAR T-cells in relapsed B-cell ALL

Relapsed and Refractory CLL/SLLПодробнее

$Relapsed and Refractory CLL/SLL$

Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory LymphomasПодробнее

$Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory Lymphomas$

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignanciesПодробнее

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

An exciting time for CAR T-cell therapy: promising results for B-ALL, nHL and CLLПодробнее

An exciting time for CAR T-cell therapy: promising results for B-ALL, nHL and CLL

Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALLПодробнее

$Optimizing CAR T-Cell Therapy in Relapsed/Refractory ALL$

CD19 Targeted CAR T-cell Therapy in LBCLПодробнее

CD19 Targeted CAR T-cell Therapy in LBCL

Durable Responses Seen With Liso-Cel for Relapsed/Refractory CLLПодробнее

$Durable Responses Seen With Liso-Cel for Relapsed/Refractory CLL$

T-Cell Therapy: Current Applications and Future DirectionsПодробнее

T-Cell Therapy: Current Applications and Future Directions

Relapsed/Refractory CLL Treatment OptionsПодробнее

$Relapsed/Refractory CLL Treatment Options$

Refractory MCL: CD19-, CD20-Targeting CAR T-Cell Therapy Has Encouraging Initial Trial ResultsПодробнее

$Refractory MCL: CD19-, CD20-Targeting CAR T-Cell Therapy Has Encouraging Initial Trial Results$

Актуальное